PT3126528T - Métodos para determinar a responsividade a inibidores de mek/erk - Google Patents

Métodos para determinar a responsividade a inibidores de mek/erk

Info

Publication number
PT3126528T
PT3126528T PT157738402T PT15773840T PT3126528T PT 3126528 T PT3126528 T PT 3126528T PT 157738402 T PT157738402 T PT 157738402T PT 15773840 T PT15773840 T PT 15773840T PT 3126528 T PT3126528 T PT 3126528T
Authority
PT
Portugal
Prior art keywords
mek
methods
erk inhibitors
determining responsiveness
responsiveness
Prior art date
Application number
PT157738402T
Other languages
English (en)
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Publication of PT3126528T publication Critical patent/PT3126528T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT157738402T 2014-04-04 2015-04-03 Métodos para determinar a responsividade a inibidores de mek/erk PT3126528T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410135569 2014-04-04

Publications (1)

Publication Number Publication Date
PT3126528T true PT3126528T (pt) 2021-09-09

Family

ID=54239415

Family Applications (2)

Application Number Title Priority Date Filing Date
PT157738402T PT3126528T (pt) 2014-04-04 2015-04-03 Métodos para determinar a responsividade a inibidores de mek/erk
PT15772589T PT3126521T (pt) 2014-04-04 2015-04-03 Gene de fusão hnf4g-rspo2

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT15772589T PT3126521T (pt) 2014-04-04 2015-04-03 Gene de fusão hnf4g-rspo2

Country Status (7)

Country Link
US (3) US10501805B2 (pt)
EP (3) EP3126521B1 (pt)
CN (3) CN106460060B (pt)
DK (2) DK3126521T3 (pt)
ES (2) ES2896404T3 (pt)
PT (2) PT3126528T (pt)
WO (2) WO2015149720A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200255901A1 (en) * 2016-08-04 2020-08-13 Shizuoka Prefecture Method for determining presence or absence of risk of developing cancer
WO2018058490A1 (zh) * 2016-09-30 2018-04-05 武汉华大吉诺因生物科技有限公司 Col14a1衍生的肿瘤抗原多肽及其应用
WO2020140927A1 (en) * 2019-01-02 2020-07-09 Crownmab Biotech Inc. Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
EP0390323B2 (en) * 1989-03-29 2012-08-08 Johns Hopkins University Detection of loss of the wild-type p53 gene
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CZ117798A3 (cs) 1995-10-23 1998-08-12 The Children's Medical Center Corporation Antiangiogenní kompozice a způsoby léčby
DK0858467T3 (da) 1995-11-23 2004-06-14 Cancer Res Campaign Tech Materialer og fremgangsmåder angående identifikationen og sekventeringen af BRCA2 cancerfölsomhedsgen og anvendelser deraf
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
BR9710362A (pt) 1996-07-13 1999-08-17 Glaxo Group Ltd Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0984930B1 (en) 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
JP2001518470A (ja) 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド 新規な血管形成阻害剤
PL340589A1 (en) 1997-11-11 2001-02-12 Pfizer Prod Inc Derivatives of thienepyrimidine and thienepyridine useful as anticarcinogenic agents
SK287132B6 (sk) 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
JP4450857B2 (ja) 2006-08-08 2010-04-14 中外製薬株式会社 Ｐｉ３ｋ阻害剤としてのピリミジン誘導体およびその用途
US20100004253A1 (en) * 2006-09-19 2010-01-07 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
CL2009000241A1 (es) 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
CN101524529B (zh) 2008-03-04 2011-09-28 中国人民解放军第二军医大学 HNF4α诱导分化治疗人体恶性实体瘤
EP2398920A4 (en) 2009-02-19 2012-10-10 Univ Cornell COMPOSITIONS AND METHODS FOR DIAGNOSIS OF PROSTATE CANCER BASED ON DETECTION OF THE FUSION STRUCTURE SCRIPT SLC45A3-ELK4
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EA201390740A1 (ru) * 2010-11-19 2013-12-30 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Способ лечения с использованием ингибитора braf
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2012106559A1 (en) * 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarkers and methods of use thereof
CN103571848B (zh) 2012-08-10 2016-06-29 安徽医科大学第一附属医院 点状掌跖角化病的致病基因及其用途

Also Published As

Publication number Publication date
EP3126528A4 (en) 2018-02-21
US20170114414A1 (en) 2017-04-27
DK3126528T3 (da) 2021-11-08
CN106536753A (zh) 2017-03-22
ES2727374T3 (es) 2019-10-15
EP3126521B1 (en) 2019-03-20
PT3126521T (pt) 2019-06-27
US10501805B2 (en) 2019-12-10
EP3126521A1 (en) 2017-02-08
CN106460060A (zh) 2017-02-22
EP4012049A3 (en) 2022-08-24
CN106536753B (zh) 2020-07-21
EP3126528A1 (en) 2017-02-08
EP3126528B1 (en) 2021-08-18
ES2896404T3 (es) 2022-02-24
DK3126521T3 (da) 2019-06-17
CN106460060B (zh) 2020-02-11
WO2015149721A1 (en) 2015-10-08
EP4012049A2 (en) 2022-06-15
US20180282814A1 (en) 2018-10-04
US20200123622A1 (en) 2020-04-23
US10683550B2 (en) 2020-06-16
WO2015149720A1 (en) 2015-10-08
EP3126521A4 (en) 2017-11-08
CN111808957A (zh) 2020-10-23

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
CL2016002736A1 (es) Inhibidores de demetilasa-1 específico de lisina
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
GB201421083D0 (en) Enzyme inhibitors
GB201421088D0 (en) New enzyme inhibitors
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
DK3191487T3 (da) Spirocykliske cathepsin-c-inhibitorer
EP3140427A4 (en) Biomarkers for response to pi3k inhibitors
GB201421085D0 (en) New enzyme inhibitors
EP3494971C0 (en) ERK INHIBITOR SALTS
GB2540917B (en) Solid acid scale inhibitors
ZA201608555B (en) Biomarkers for response to ezh2 inhibitors
GB201400299D0 (en) Corrosion inhibitors
PT3126528T (pt) Métodos para determinar a responsividade a inibidores de mek/erk
EP3237887C0 (en) METHOD FOR DETERMINING SURFACE-RELATED RESISTANCE
GB201418154D0 (en) Inhibitors
GB201400300D0 (en) Corrosion inhibitors
GB201320835D0 (en) HIF inhibitors